LU91136I2 - 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)-méthoxy-3-hydroxy-1-propanyl-L-valinate et les sels pharmaceutiquement acceptables de celui-ci (valcyte). - Google Patents

2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)-méthoxy-3-hydroxy-1-propanyl-L-valinate et les sels pharmaceutiquement acceptables de celui-ci (valcyte).

Info

Publication number
LU91136I2
LU91136I2 LU91136C LU91136C LU91136I2 LU 91136 I2 LU91136 I2 LU 91136I2 LU 91136 C LU91136 C LU 91136C LU 91136 C LU91136 C LU 91136C LU 91136 I2 LU91136 I2 LU 91136I2
Authority
LU
Luxembourg
Prior art keywords
purin
dihydro
oxo
methoxy
amino
Prior art date
Application number
LU91136C
Other languages
English (en)
Original Assignee
Hoffmann Kla Roche Ag F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23079211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91136(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann Kla Roche Ag F filed Critical Hoffmann Kla Roche Ag F
Publication of LU91136I2 publication Critical patent/LU91136I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
LU91136C 1994-07-28 2003-05-21 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)-méthoxy-3-hydroxy-1-propanyl-L-valinate et les sels pharmaceutiquement acceptables de celui-ci (valcyte). LU91136I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28189394A 1994-07-28 1994-07-28

Publications (1)

Publication Number Publication Date
LU91136I2 true LU91136I2 (fr) 2005-07-06

Family

ID=23079211

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91136C LU91136I2 (fr) 1994-07-28 2003-05-21 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)-méthoxy-3-hydroxy-1-propanyl-L-valinate et les sels pharmaceutiquement acceptables de celui-ci (valcyte).

Country Status (33)

Country Link
EP (1) EP0694547B1 (fr)
JP (1) JP3090305B2 (fr)
KR (1) KR100358626B1 (fr)
CN (1) CN1045089C (fr)
AT (1) ATE179173T1 (fr)
AU (1) AU697107B2 (fr)
BR (1) BR9503468A (fr)
CA (1) CA2154721C (fr)
CO (1) CO4410181A1 (fr)
CY (2) CY2180B1 (fr)
CZ (1) CZ290511B6 (fr)
DE (3) DE10299032I2 (fr)
DK (1) DK0694547T3 (fr)
ES (1) ES2083348T3 (fr)
FI (1) FI112080B (fr)
GR (2) GR960300021T1 (fr)
HK (1) HK1012339A1 (fr)
HU (1) HU216867B (fr)
IL (1) IL114735A (fr)
LU (1) LU91136I2 (fr)
MA (1) MA23631A1 (fr)
MY (1) MY114393A (fr)
NL (1) NL300071I2 (fr)
NO (2) NO312899B1 (fr)
NZ (1) NZ272652A (fr)
PE (1) PE32296A1 (fr)
PL (1) PL180609B1 (fr)
RU (1) RU2133749C1 (fr)
SA (1) SA95160158B1 (fr)
TR (1) TR199500895A2 (fr)
TW (1) TW434242B (fr)
UY (1) UY24006A1 (fr)
ZA (1) ZA956228B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
WO1997027194A1 (fr) * 1996-01-26 1997-07-31 F. Hoffmann-La Roche Ag Procede pour preparer des derives de la purine
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
ES2180923T5 (es) * 1996-01-26 2005-10-16 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de purina.
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6184376B1 (en) 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
ATE227289T1 (de) * 1997-02-10 2002-11-15 Medivir Ab Verfahren zur herstellung von azyklischen nukleosiden
JP3844654B2 (ja) * 1997-08-15 2006-11-15 メディヴィル・アクチボラグ レトロウイルス逆転写酵素およびｂ型肝炎ウイルス（ｈｂｖ）のｄｎａポリメラーゼのインヒビターを含む抗ウイルス剤などのヌクレオシドアナログ
AU1711599A (en) * 1997-12-19 1999-07-12 Bristol-Myers Squibb Company Prodrugs of lobucavir and methods of use
WO1999051613A1 (fr) * 1998-04-03 1999-10-14 Medivir Ab Promedicaments de produits pharmaceutiques contenant du phosphore
KR20030015655A (ko) * 2001-08-17 2003-02-25 한미약품공업 주식회사 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물
ATE361910T1 (de) * 2002-04-23 2007-06-15 Aventis Pharma Inc 3-(pyridinyl-amino)-1h-indol-2-carbonsäure- verbindungen als inhibitoren der interleukin-4 genexpression
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
WO2005021549A1 (fr) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Chlorhydrate de valganciclovir amorphe
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
UA103758C2 (ru) * 2004-07-19 2013-11-25 Биокон Лимитед Конъюгаты олигомеров инсулина, их композиции и применение
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ZA200702234B (en) * 2006-03-21 2008-07-30 Cipla Ltd Preparation of ester of purine derivatives
US8173158B2 (en) 2007-10-12 2012-05-08 Takeda Pharmaceuticals U.S.A., Inc. Methods of treating gastrointestinal disorders independent of the intake of food
WO2012163373A1 (fr) * 2011-05-31 2012-12-06 Pharmathen S.A. Procédé de préparation d'un composé de 2-amino-9-((2-phényl-1,3-dioxan- 5-yloxy)-méthyl)-1h-purin-6(9h)-one utile dans la préparation du valganciclovir
KR102312533B1 (ko) 2021-02-24 2021-10-15 주식회사 이웅 자동 스패너

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
ES8705889A1 (es) * 1984-12-12 1987-06-01 Syntex Inc Un metodo para preparar eteres alcaximetilicos y esteres alcoximetilicos de derivados de guananina.
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
US5043339A (en) * 1988-12-19 1991-08-27 Burroughs Wellcome Co. Antiviral compounds

Also Published As

Publication number Publication date
RU95113148A (ru) 1997-06-27
IL114735A (en) 1998-06-15
FI112080B (fi) 2003-10-31
NZ272652A (en) 1996-12-20
UY24006A1 (es) 2001-07-31
ZA956228B (en) 1996-02-22
EP0694547A2 (fr) 1996-01-31
CY2004003I1 (el) 2009-11-04
EP0694547A3 (fr) 1996-06-05
CZ193995A3 (en) 1996-02-14
DE10299032I1 (de) 2003-01-23
CA2154721A1 (fr) 1996-01-29
JP3090305B2 (ja) 2000-09-18
BR9503468A (pt) 1996-02-27
KR960004345A (ko) 1996-02-23
JPH0841061A (ja) 1996-02-13
CY2004003I2 (el) 2009-11-04
AU2719595A (en) 1996-02-08
EP0694547B1 (fr) 1999-04-21
CA2154721C (fr) 2001-01-02
CN1122804A (zh) 1996-05-22
NL300071I2 (nl) 2002-03-01
DE694547T1 (de) 1996-10-24
DE69509173D1 (de) 1999-05-27
HU216867B (hu) 1999-09-28
AU697107B2 (en) 1998-09-24
IL114735A0 (en) 1995-11-27
CO4410181A1 (es) 1997-01-09
KR100358626B1 (ko) 2003-01-14
DK0694547T3 (da) 2000-01-03
ES2083348T1 (es) 1996-04-16
DE10299032I2 (de) 2006-06-14
NL300071I1 (nl) 2002-02-01
PL309812A1 (en) 1996-02-05
TR199500895A2 (tr) 1996-06-21
HUT73246A (en) 1996-07-29
GR3030678T3 (en) 1999-11-30
SA95160158B1 (ar) 2006-05-20
CZ290511B6 (cs) 2002-08-14
DE69509173T2 (de) 1999-10-21
PE32296A1 (es) 1996-08-07
ATE179173T1 (de) 1999-05-15
GR960300021T1 (en) 1996-04-30
MA23631A1 (fr) 1996-04-01
CY2180B1 (en) 2002-08-23
PL180609B1 (pl) 2001-03-30
NO952977L (no) 1996-01-29
NO2003001I2 (no) 2007-06-11
MY114393A (en) 2002-10-31
HK1012339A1 (en) 1999-07-30
FI953592A (fi) 1996-01-29
CN1045089C (zh) 1999-09-15
TW434242B (en) 2001-05-16
NO312899B1 (no) 2002-07-15
NO952977D0 (no) 1995-07-27
HU9502238D0 (en) 1995-09-28
ES2083348T3 (es) 1999-08-01
FI953592A0 (fi) 1995-07-27
RU2133749C1 (ru) 1999-07-27

Similar Documents

Publication Publication Date Title
LU91136I2 (fr) 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)-méthoxy-3-hydroxy-1-propanyl-L-valinate et les sels pharmaceutiquement acceptables de celui-ci (valcyte).
PT97890A (pt) Processo para a preparacao de ftalidas substituidas e de ftalidas heterociclicas
FI940102A0 (fi) Foerfarande och anordning foer hoejande av en materialbanas glans och ytjaemnhet
MX9204190A (es) Derivdos de 2-(4-hidroxipiperidino)-1-alcanol como agentes antiisquemicos.
NO972843L (no) Maskinfresing med laserstråle
NO912979D0 (no) Fremgangsmaate for fremstilling av 2-(9-fluorenoyl)-carbapenederivater.
IT1243410B (it) Procedimento per la funzionalizzazione di trifluorometilbenzeni
FI932704A0 (fi) Foerfarande och anordning foer avlaegsnande av avlagringar fraon processanordningarnas vaeggar
ITTO930115A1 (it) Testa di focalizzazione laser.
SG32424A1 (en) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1, 3-propanediol derivative
FI901953A (fi) Foerfarande och anordning foer rengoering av roekgaser.